Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | nmda type glutamate receptor | 0.0088 | 1 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0063 | 0 | 0.5 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0063 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0063 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0063 | 0 | 0.5 |
Chlamydia trachomatis | glutamine binding protein | 0.0063 | 0 | 0.5 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0088 | 1 | 1 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0063 | 0 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0079 | 0.6501 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 66 uM | Displacement of labeled SRC2-2 from human TRbeta expressed in BL21 (DE3) cells FP assay | ChEMBL. | 17918822 |
IC50 (binding) | = 66 uM | Displacement of labeled SRC2-2 from human TRbeta expressed in BL21 (DE3) cells FP assay | ChEMBL. | 17918822 |
IC50 (binding) | = 71 uM | Displacement of labeled SRC2-2 from human TRalpha by FP assay | ChEMBL. | 17918822 |
IC50 (binding) | = 71 uM | Displacement of labeled SRC2-2 from human TRalpha by FP assay | ChEMBL. | 17918822 |
LD50 (functional) | = 9.9 uM | Cytotoxicity against human ARO cells after 48 hrs by MTS assay | ChEMBL. | 17918822 |
LD50 (functional) | = 9.9 uM | Cytotoxicity against human ARO cells after 48 hrs by MTS assay | ChEMBL. | 17918822 |
LD50 (functional) | = 25.6 uM | Cytotoxicity against human U2OS cells after 48 hrs by MTS assay | ChEMBL. | 17918822 |
LD50 (functional) | = 25.6 uM | Cytotoxicity against human U2OS cells after 48 hrs by MTS assay | ChEMBL. | 17918822 |
Ratio IC50 (binding) | = 1.1 | Selectivity ratio of IC50 for TRBeta to IC50 for TRalpha | ChEMBL. | 17918822 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.